Melissa Epperly Sells 17,750 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Melissa Epperly sold 17,750 shares of Roivant Sciences stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $34.38, for a total value of $610,245.00. Following the sale, the director owned 16,474 shares in the company, valued at $566,376.12. This represents a 51.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Roivant Sciences Stock Up 0.3%

Shares of ROIV opened at $35.13 on Friday. The firm has a market cap of $25.27 billion, a price-to-earnings ratio of -58.55 and a beta of 1.11. The business’s 50 day moving average is $30.12 and its two-hundred day moving average is $27.21. Roivant Sciences Ltd. has a 52-week low of $10.70 and a 52-week high of $35.90.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings results on Wednesday, May 20th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of ($0.29) by $0.57. The business had revenue of $2.52 million for the quarter, compared to analysts’ expectations of $3.41 million. Roivant Sciences had a negative net margin of 3,629.19% and a negative return on equity of 20.54%. During the same quarter last year, the company posted ($0.29) earnings per share. On average, equities analysts expect that Roivant Sciences Ltd. will post -1.83 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently commented on ROIV. Sanford C. Bernstein initiated coverage on Roivant Sciences in a research report on Friday, March 20th. They issued an “outperform” rating and a $35.00 target price for the company. Citigroup upped their price target on Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, May 21st. Guggenheim raised their price objective on Roivant Sciences from $30.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, May 26th. Leerink Partners set a $42.00 price objective on shares of Roivant Sciences in a report on Thursday, May 21st. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Roivant Sciences in a report on Thursday, May 21st. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $33.59.

Hedge Funds Weigh In On Roivant Sciences

A number of hedge funds and other institutional investors have recently bought and sold shares of ROIV. Fifth Third Bancorp grew its holdings in shares of Roivant Sciences by 8.7% in the 1st quarter. Fifth Third Bancorp now owns 4,686 shares of the company’s stock worth $130,000 after acquiring an additional 376 shares during the last quarter. Bessemer Group Inc. lifted its holdings in shares of Roivant Sciences by 21.8% during the first quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock valued at $69,000 after purchasing an additional 441 shares during the last quarter. Fifth Third Wealth Advisors LLC lifted its holdings in shares of Roivant Sciences by 4.6% during the first quarter. Fifth Third Wealth Advisors LLC now owns 10,166 shares of the company’s stock valued at $282,000 after purchasing an additional 445 shares during the last quarter. Versant Capital Management Inc boosted its position in shares of Roivant Sciences by 13.9% in the 2nd quarter. Versant Capital Management Inc now owns 3,995 shares of the company’s stock valued at $141,000 after purchasing an additional 487 shares during the period. Finally, Oregon Public Employees Retirement Fund boosted its position in shares of Roivant Sciences by 0.6% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company’s stock valued at $1,891,000 after purchasing an additional 500 shares during the period. 64.76% of the stock is currently owned by institutional investors and hedge funds.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.